Skip to main content
TipRanks
Go Ultimate75% OFF

Amphastar Pharmaceuticals (29A) Drug Pipeline

2 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
I004, NovologPharmacokinetics, Pharmacodynamics, Insulin Aspartphase2AndPhase3CompletedComparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy VolunteersApr 24, 2026―
I004, NovologPharmacokinetics, Pharmacodynamicsphase2AndPhase3CompletedComparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy VolunteersSep 12, 2022―
Epinephrine, Epinephrine Injection Auto-Injector, Albuterol SulfateAsthma, Pharmacokinetics, Epinephrine, Albuterol, AnaphylaxisPhase IVCompletedStudy of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy IndividualsDec 19, 2019―
A006 Dpi, Proventil MdiAsthmaPhase IICompletedEvaluation of Pharmacokinetics and Safety of A006 in Healthy VolunteersOct 20, 2014―
A006 Dpi, Proventil MdiAsthmaPhase IICompletedAlbuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety EvaluationAug 04, 2014―
Epinephrine Hfa-MdiAsthmaPhase IIICompletedEvaluation of Efficacy and Safety for Single Dose of E004 in Children With AsthmaNov 20, 2012―
Arm T Epinephrine Inhalation Aerosol Hfa, 125 Mcg, 1 Inhalation, Arm C-Epinephrine Inhalation Aerosol CfcAsthmaphase1AndPhase2TerminatedAssessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy AdultsNov 20, 2012―
Saline, Hyaluronidase, HistamineAllergic Skin ReactionPhase IICompletedEvaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)Sep 13, 2012―
Albuterol Dpi 25 Mcg/Inh, Albuterol Dpi 90 Mcg/Inh, Albuterol Mdi 90 Mcg/InhAsthmaPhase IICompletedAlbuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety EvaluationApr 17, 2012―
Primatene Mist, Epinephrine InhalationAsthmaPhase IIICompletedSafety Study in Adolescent and Adult Patients With AsthmaNov 15, 2011―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Amphastar Pharmaceuticals Inc (DE:29A) have in its pipeline
Amphastar Pharmaceuticals DE:29A is currently developing the following drugs: I004, Novolog, Epinephrine, Epinephrine Injection Auto-Injector, Albuterol Sulfate, A006 Dpi, Proventil Mdi, Epinephrine Hfa-Mdi, Arm T Epinephrine Inhalation Aerosol Hfa, 125 Mcg, 1 Inhalation, Arm C-Epinephrine Inhalation Aerosol Cfc, Saline, Hyaluronidase, Histamine, Albuterol Dpi 25 Mcg/Inh, Albuterol Dpi 90 Mcg/Inh, Albuterol Mdi 90 Mcg/Inh, Primatene Mist, Epinephrine Inhalation, E004 Hfa-Mdi, Epinephrine Inhalation Aerosol, Arm T1: Primatene Mist Hfa, Arm T2: Primatene Mist Hfa, Arm C: Primatene Mist, Epinephrine Inhalation Aerosol, Epinephrine Inhalation Aerosol, Hfa, A006, Proventil-Hfa, Albuterol Inhalation Powder, Albuterol Inhalation Aerosol, E004, 90 Mcg/Actuation, E004, 125 Mcg, E004, 220 Mcg, Epinephrine Inhalation Aerosol, Cfc Propelled, E004, 160 Mcg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.